Mount Sinai is first in New York state to perform new Alzheimer's imaging test in clinical setting
The Mount Sinai Medical Center is the first institution in New York State to use in the clinical setting a newly approved imaging technique to detect Alzheimer's disease (AD) in people who are cognitively impaired. Until now, physicians have been limited in their ability to diagnose AD, guided almost exclusively by a patient's mental and behavioral symptoms and family history. The innovative techniquerecently approved by the U.S. Food and Drug Administration (FDA), is not only expected to play a critical role in the diagnosis of AD, but in drug research, and the design of clinical trials leading to a cure.
Under the new procedure, patients are injected with a radioactive agent called florbetapir, which binds to the plaques that are hallmark symptoms of AD. The physician then uses a positron emission tomography (PET) scan to highlight the plaques that are binded to the agent. If a large amount of florbetapir is visualized on the image, the patient may have AD. If no plaques are found, this could eliminate AD as a possible cause of the patient's cognitive impairment.
"Until now, a diagnosis of Alzheimer's disease could only be pathologically confirmed at autopsy," said Samuel Gandy, MD, Professor of Neurology and Psychiatry and Director of the Mount Sinai Center for Cognitive Health and NFL Neurological Center at The Mount Sinai Medical Center. "Coupled with traditional clinical examination, florbetapir is a promising tool in helping confirm the diagnosis of a patient who is dealing with cognitive impairment. While we cannot exclude the presence of very low levels of amyloid, a negative test means that a memory problem is likely due to some other cause."
Alzheimer's disease is one of several possible causes of cognitive decline. Symptoms may overlap with other causes of cognitive impairment including memory loss; loss in visuospatial ability and executive function; and behavioral and language difficulties. The imaging technique will be used as an adjunctive tool with traditional methods of diagnosis to help determine if these symptoms are related to AD and if not, eliminate it as a likely cause of them.
"The approval of this agent by the FDA for PET imaging of the brain, already available at The Mount Sinai Medical Center, marks a significant advance in the evaluation of patients suspected of having or being at risk for Alzheimer's Disease," said Josef Machac, MD, Director of Nuclear Medicine and Professor of Radiology at The Mount Sinai Medical Center. "The principal value of this procedure at this time is in excluding beta-amyloid and Alzheimer's disease as cause for memory or cognitive decline. This can help in patient management, and in clinical trials of investigational therapies to find more effective treatment."
Florbetapir is anticipated to be most useful in the research setting, providing scientists with a tool for measuring the efficacy of certain drugs on patients who present with cognitive impairment or AD. The scan will help determine which patients are appropriate for which trials, which drugs are effective and for what duration, and provide a better assessment for disease progression.
"From a research perspective, this imaging technique is a major advance that will propel us forward in designing clinical trials and determining drug efficacy for this debilitating disease," said Dr. Gandy. "I look forward to using it both in my clinical practice to help diagnose my patients, and in my research on the quest for a cure for Alzheimer's disease."
Provided by The Mount Sinai Hospital
- Advance toward an imaging agent for diagnosing Alzheimer's disease Jan 11, 2012 | not rated yet | 0
- Imaging procedure can identify biomarker associated with Alzheimer's disease Jan 18, 2011 | not rated yet | 0
- Neuroimaging may shed light on how Alzheimer's disease develops Jan 11, 2010 | not rated yet | 0
- Indications of Alzheimer's disease may be evident decades before first signs of cognitive impairment Mar 28, 2011 | not rated yet | 0
- PET-CT exams help identify cognitive reserve in early-onset Alzheimer's disease May 02, 2011 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Force Between Two Concentric Solenoids
2 hours ago Imagine a finite length solenoid with outer radius R1 and inner radius R2. This solenoid has a time-varying current going though it. This solenoid is...
Synchrotron, question about insertion devices and electron velocity
2 hours ago When an electron enters an insertion device (wiggler and undulator) from the storage ring in a synchrotron the tangential velocity is equal to the...
Equating differentials => equating coefficients
4 hours ago Hi all, In thermodynamics one often has equations like A dx + B dy = ∂f/∂x dx + ∂f/∂y dy From which follows A = ∂f/∂x B = ∂f/∂y
The idea behind a reverse shock
10 hours ago So in a supernova explosion for example (5th slide) http://www.astro.princeton.edu/~burrows/classes/541/blastwavesChisari.pdf Ambient medium is...
Guass's Law for a charge distribution
10 hours ago First, this is not a homework question, just something I've been confused about for some time. I understand how to use Guass's law in many ways but...
11 hours ago Hello :) i'm new to this forum, so excuse me for my straightforwardness ;) I'm working on my bachelor work and i can't find a solution. I'm writing...
- More from Physics Forums - Classical Physics
More news stories
In the search for medication against Alzheimer's disease, scientists have focused – among other factors – on drugs that can break down Amyloid beta (A-beta). After all, it is the accumulation of A-beta that causes the ...
Alzheimer's disease & dementia May 24, 2013 | not rated yet | 0
(Medical Xpress)—The way Alzheimer's disease is portrayed by advocacy groups and the media is having undue influence on the euthanasia debate, according to a Deakin University nursing ethics professor.
Alzheimer's disease & dementia May 24, 2013 | not rated yet | 2
Cinnamon: Can the red-brown spice with the unmistakable fragrance and variety of uses offer an important benefit? The common baking spice might hold the key to delaying the onset of –– or warding off ...
Alzheimer's disease & dementia May 23, 2013 | 5 / 5 (5) | 0 |
An anti-cancer drug reverses memory deficits in an Alzheimer's disease mouse model, University of Pittsburgh Graduate School of Public Health researchers confirm in the journal Science.
Alzheimer's disease & dementia May 23, 2013 | not rated yet | 0 |
Teams of highly respected Alzheimer's researchers failed to replicate what appeared to be breakthrough results for the treatment of this brain disease when they were published last year in the journal Science.
Alzheimer's disease & dementia May 23, 2013 | 3 / 5 (2) | 3 |
Coenzyme Q10 decreases all cause mortality by half, according to the results of a multicentre randomised double blind trial presented today at Heart Failure 2013 congress. It is the first drug to improve heart failure mortality ...
16 hours ago | 5 / 5 (2) | 5
(HealthDay)—Animals make great companions for senior citizens, but elderly people who always drive with a pet in the car are far more likely to crash than those who never drive with a pet, researchers have ...
8 hours ago | not rated yet | 1
Heart failure accelerates the aging process and brings on early andropausal syndrome (AS), according to research presented today at the Heart Failure Congress 2013. AS, also referred to as male 'menopause', was four times ...
16 hours ago | not rated yet | 1
Mortality and length of stay are highest in heart failure patients admitted in January, on Friday, and overnight, according to research presented today at the Heart Failure Congress 2013. The analysis of nearly 1 million ...
16 hours ago | not rated yet | 0
(AP)—Department of Justice lawyers have again asked a federal appeals court in New York to delay lifting age restrictions and prescription requirements on an emergency contraceptive popularly known as the morning-after ...
16 hours ago | not rated yet | 0